294 related articles for article (PubMed ID: 17575366)
1. Acromegaly associated with type 2 diabetes showing normal IGF-1 levels under poorly controlled glycemia.
Lim DJ; Kwon HS; Cho JH; Kim SH; Choi YH; Yoon KH; Cha BY; Lee KW; Son HY; Kang SK
Endocr J; 2007 Aug; 54(4):537-41. PubMed ID: 17575366
[TBL] [Abstract][Full Text] [Related]
2. Acromegaly with normal growth hormone levels: response to Sandostatin-LAR treatment.
Shimon I; Nass D; Hadani M
Pituitary; 2000 May; 2(4):289-94. PubMed ID: 11081151
[TBL] [Abstract][Full Text] [Related]
3. Acromegaly with normal IGF-1 levels probably due to poorly controlled diabetes mellitus.
Arihara Z; Sakurai K; Yamada S; Murakami O; Takahashi K
Tohoku J Exp Med; 2008 Dec; 216(4):325-9. PubMed ID: 19060447
[TBL] [Abstract][Full Text] [Related]
4. Type 1 diabetes associated with asymptomatic acromegaly successfully treated with surgery after pregnancy: a case report.
Iwai H; Ito H; Ri S; Harada T; Hirota N; Yamauchi T; Miyatake T; Ohno Y; Aoki N
Endocr J; 2005 Aug; 52(4):413-20. PubMed ID: 16127208
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis of acromegaly in a patient with type 1 diabetes mellitus.
Hofmann EA; Polonsky KS; Weiss RE
Endocr Pract; 2002; 8(2):113-8. PubMed ID: 11942776
[TBL] [Abstract][Full Text] [Related]
6. Hormonal diagnosis of GH hypersecretory states.
Grottoli S; Gasco V; Ragazzoni F; Ghigo E
J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
[TBL] [Abstract][Full Text] [Related]
7. Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients.
De Marinis L; Mancini A; Bianchi A; Gentilella R; Valle D; Giampietro A; Zuppi P; Anile C; Maira G; Giustina A
Metabolism; 2002 May; 51(5):616-21. PubMed ID: 11979395
[TBL] [Abstract][Full Text] [Related]
8. Acromegaly presenting with low insulin-like growth factor-1 levels and diabetes: a case report.
Wijayaratne DR; Arambewela MH; Dalugama C; Wijesundera D; Somasundaram N; Katulanda P
J Med Case Rep; 2015 Oct; 9():241. PubMed ID: 26514337
[TBL] [Abstract][Full Text] [Related]
9. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
[TBL] [Abstract][Full Text] [Related]
10. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
11. Metabolic glucose status and pituitary pathology portend therapeutic outcomes in acromegaly.
Cheng S; Al-Agha R; Araujo PB; Serri O; L Asa S; Ezzat S
PLoS One; 2013; 8(9):e73543. PubMed ID: 24039977
[TBL] [Abstract][Full Text] [Related]
12. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
13. Percent reduction of growth hormone levels correlates closely with percent resected tumor volume in acromegaly.
Schwyzer L; Starke RM; Jane JA; Oldfield EH
J Neurosurg; 2015 Apr; 122(4):798-802. PubMed ID: 25423276
[TBL] [Abstract][Full Text] [Related]
14. Clinical-biochemical correlations in acromegaly at diagnosis and the real prevalence of biochemically discordant disease.
Mercado M; Espinosa de los Monteros AL; Sosa E; Cheng S; Mendoza V; Hernández I; Sandoval C; Guinto G; Molina M
Horm Res; 2004; 62(6):293-9. PubMed ID: 15542931
[TBL] [Abstract][Full Text] [Related]
15. Elevated serum growth hormone in a patient with Type 1 diabetes: a diagnostic dilemma.
Herlihy OM; Perros P
Diabetes Metab Res Rev; 2000; 16(3):211-6. PubMed ID: 10867721
[TBL] [Abstract][Full Text] [Related]
16. Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance.
Matta MP; Couture E; Cazals L; Vezzosi D; Bennet A; Caron P
Eur J Endocrinol; 2008 Mar; 158(3):305-10. PubMed ID: 18299462
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic utility of serum GH, IGF-1 and IGFBP3 in patients of acromegaly with uncontrolled diabetes: a pilot study.
Dutta P; Singhal S; Sachdeva NK; Shah VN; Pathak A; Mukherjee KK; Bhansali A
J Assoc Physicians India; 2014 Aug; 62(8):686-90. PubMed ID: 25856936
[TBL] [Abstract][Full Text] [Related]
18. [Acromegaly and pregnancy: report of six new cases].
Persechini ML; Gennero I; Grunenwald S; Vezzosi D; Bennet A; Caron P
J Gynecol Obstet Biol Reprod (Paris); 2014 Nov; 43(9):704-12. PubMed ID: 24035359
[TBL] [Abstract][Full Text] [Related]
19. Clinical Characteristics of Acromegalic Patients With Paradoxical GH Response to Oral Glucose Load.
Mukai K; Otsuki M; Tamada D; Kitamura T; Hayashi R; Saiki A; Goto Y; Arita H; Oshino S; Morii E; Saitoh Y; Shimomura I
J Clin Endocrinol Metab; 2019 May; 104(5):1637-1644. PubMed ID: 30476255
[TBL] [Abstract][Full Text] [Related]
20. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
